Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics plc : Holding(s) in Company

Notification of major interests in shares

Summit highlights Microbiome Preservation during Ridinilazole treatment

Summit has announced that at ID Week 2017, it presented further positive gut microbiome data of ridinilazole from its ex...

Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017

A statement giving an update on research (e.g. clinical trials)

Summit Therapeutics plc : Exercise of Options

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

All News

DateHeadlineSource
13-10-17Summit Therapeutics plc : Holding(s) in CompanyRNS
09-10-17Summit highlights Microbiome Preservation during Ridinilazole treatmentStockMarketWire
09-10-17Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017RNS
05-10-17Summit Therapeutics plc : Exercise of OptionsRNS
04-10-17Summit to present at conference in Saint-MaloStockMarketWire
04-10-17Summit Highlights DMD Biomarker Validation Data at 22nd WMS CongressRNS
03-10-17Summit Therapeutics plc : Exercise of OptionsRNS
02-10-17Summit to host R&D dayStockMarketWire
02-10-17Summit Therapeutics to Host R&D Day 11 October 2017RNS
29-09-17Summit Therapeutics plc : Exercise of Share OptionsRNS
29-09-17Best AIM companies of 2017 Interactive Investor
28-09-17Summit Therapeutics plc : Exercise of Share OptionsRNS
25-09-17Summit joins cTAPStockMarketWire
25-09-17Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMDRNS
21-09-17Summit Therapeutics plc : Holding(s) in CompanyRNS
20-09-17Summit Therapeutics plc : Holding(s) in CompanyRNS
18-09-17Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before ExpensesRNS
15-09-17Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment OptionRNS
14-09-17Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before ExpensesRNS
11-09-17Summit awarded Barda contract worth up to $62mStockMarketWire
11-09-17Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDIRNS
05-09-17Summit announces positive ridinilazole trial resultsStockMarketWire
05-09-17Summit Therapeutics plc : Positive Top-line Phase 2 ResultsRNS
31-08-17Summit Therapeutics plc : Half-yearly reportRNS
25-08-17Summit Therapeutics plc : Notice of ResultsRNS
03-08-17Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceRNS
31-07-17Summit Therapeutics plc : Total voting rightsRNS
19-07-17Summit Therapeutics plc : Grant of Share Options and Restricted Stock UnitsRNS
18-07-17Summit Therapeutics plc : Result of AGMRNS
28-06-17Summit Therapeutics plc : Exercise of Share OptionsRNS
28-06-17Summit Therapeutics plc : Grant of Share OptionsRNS
22-06-17Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS CongressRNS
16-06-17Four AIM shares for a post-election worldInteractive Investor
15-06-17Summit Therapeutics to Participate in JMP Securities Life Sciences ConferenceRNS
14-06-17Summit losses fallStockMarketWire
14-06-17Summit Therapeutics plc : 1st Quarter ResultsRNS
13-06-17Summit confirms date of Q1 results announcementStockMarketWire
13-06-17Summit Therapeutics plc : Notice of ResultsRNS
05-06-17Summit highlights benefits of ridinilazole at ASM MicrobeStockMarketWire
05-06-17Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017RNS

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory